SG10202110908WA - Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof - Google Patents
Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereofInfo
- Publication number
- SG10202110908WA SG10202110908WA SG10202110908WA SG10202110908WA SG10202110908WA SG 10202110908W A SG10202110908W A SG 10202110908WA SG 10202110908W A SG10202110908W A SG 10202110908WA SG 10202110908W A SG10202110908W A SG 10202110908WA SG 10202110908W A SG10202110908W A SG 10202110908WA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- activatable
- activatable anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562156835P | 2015-05-04 | 2015-05-04 | |
US201562220805P | 2015-09-18 | 2015-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202110908WA true SG10202110908WA (en) | 2021-11-29 |
Family
ID=55967468
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110908WA SG10202110908WA (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
SG10201913767VA SG10201913767VA (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913767VA SG10201913767VA (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Country Status (21)
Country | Link |
---|---|
US (3) | US10745481B2 (fr) |
EP (2) | EP3708585A1 (fr) |
JP (2) | JP7028648B2 (fr) |
KR (1) | KR20180010203A (fr) |
CN (2) | CN107849133B (fr) |
AU (1) | AU2016257929B2 (fr) |
BR (1) | BR112017023872A2 (fr) |
CA (1) | CA2984948A1 (fr) |
DK (1) | DK3292150T3 (fr) |
EA (1) | EA201792414A1 (fr) |
ES (1) | ES2796698T3 (fr) |
HK (1) | HK1250036A1 (fr) |
HR (1) | HRP20200721T1 (fr) |
HU (1) | HUE049866T2 (fr) |
IL (2) | IL292798A (fr) |
MX (2) | MX2017014136A (fr) |
PL (1) | PL3292150T3 (fr) |
PT (1) | PT3292150T (fr) |
RS (1) | RS60222B1 (fr) |
SG (2) | SG10202110908WA (fr) |
WO (1) | WO2016179285A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
CN118146306A (zh) | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス,インコーポレイティド | マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
JP7001615B2 (ja) | 2016-11-28 | 2022-02-03 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
CN110214151A (zh) | 2016-11-28 | 2019-09-06 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
KR20190089034A (ko) | 2016-12-09 | 2019-07-29 | 시애틀 지네틱스, 인크. | 코일드 코일에 의해 차폐된 이가 항체 |
JP2020531045A (ja) * | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd166抗体およびその使用 |
WO2019036433A2 (fr) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | Anticorps sous forme de promédicaments, promédicaments à base de ceux-ci, leurs procédés d'utilisation et de préparation |
WO2019036855A1 (fr) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Molécules anti-cd137 et leur utilisation |
CN111212853A (zh) * | 2017-08-30 | 2020-05-29 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
EP3679068A2 (fr) * | 2017-09-08 | 2020-07-15 | Maverick Therapeutics, Inc. | Fractions de liaison à activation conditionnelle contenant des régions fc |
IL302614A (en) * | 2017-09-08 | 2023-07-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
SG11202004897XA (en) | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Polypeptide including antigen-binding domain and carrying section |
TWI818934B (zh) | 2017-11-28 | 2023-10-21 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
WO2019148445A1 (fr) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation |
WO2019148444A1 (fr) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation |
EP3769309A1 (fr) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systèmes et procédés de modélisation pharmacologique quantitative d'espèces d'anticorps activables chez des sujets mammifères |
AU2019271148B2 (en) | 2018-05-14 | 2023-07-06 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
SG11202011309SA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of use thereof |
EP3816182A4 (fr) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à un ligand contenant un anticorps à domaine unique |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
KR20210098989A (ko) * | 2018-11-02 | 2021-08-11 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항-cd166 항체 및 이의 사용 방법 |
WO2020180398A1 (fr) * | 2019-01-14 | 2020-09-10 | The Regents Of The University Of California | Compositions et procédés de modulation de l'internalisation cellulaire |
CN113677372A (zh) * | 2019-02-26 | 2021-11-19 | 西托姆克斯治疗公司 | 可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法 |
EP3934762A1 (fr) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Protéines de liaison à activation conditionnelle limitée |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
CN113631194A (zh) | 2019-03-21 | 2021-11-09 | 伊缪诺金公司 | 制备细胞结合剂-药物缀合物的方法 |
KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
EP3958977B1 (fr) | 2019-04-26 | 2023-09-13 | ImmunoGen, Inc. | Dérivés de camptothécine |
CN114450022A (zh) | 2019-05-14 | 2022-05-06 | 狼人治疗公司 | 分离部分及其使用方法 |
WO2020236679A1 (fr) * | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Méthodes et compositions pour déterminer la biodistribution de conjugués anticorps anti-cd166 activables |
TW202112808A (zh) | 2019-06-05 | 2021-04-01 | 日商中外製藥股份有限公司 | 抗體切斷部位結合分子 |
US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法 |
MX2022011780A (es) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics Inc | Composiciones que contienen anticuerpos activables. |
US20240000960A1 (en) * | 2020-11-16 | 2024-01-04 | The Cleveland Clinic Foundation | Anti-cd6 antibody conjugates for treating t-cell mediated disorders and t-cell lymphoma/leukemia |
JP2024505600A (ja) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | 結合剤およびそれを使用する方法 |
IL312143A (en) | 2021-10-15 | 2024-06-01 | Amgen Inc | An activatable polypeptide complex |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
WO2023086897A1 (fr) * | 2021-11-12 | 2023-05-19 | University Of Florida Research Foundation, Incorporated | Anticorps anti-siglec-6, composés dérivés et utilisations associées |
CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
WO2023183888A1 (fr) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Constructions de protéines de liaison à l'antigène activables et leurs utilisations |
WO2023183923A1 (fr) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Molécules masquées à double ancrage activables et leurs procédés d'utilisation |
WO2023192606A2 (fr) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Protéines de liaison au cd3 et leurs procédés d'utilisation |
WO2023192973A1 (fr) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Molécules multispécifiques activables et leurs méthodes d'utilisation |
WO2023222580A1 (fr) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Nouveaux anticorps masqués |
WO2024015830A1 (fr) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Immunoconjugués epcam et leurs utilisations |
WO2024030850A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Substrats à protéase clivable et procédé d'utilisation associé |
WO2024030843A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et leurs procédés d'utilisation |
WO2024030845A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et procédés d'utilisation associés |
WO2024030847A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et procédés d'utilisation associés |
WO2024030858A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Substrats clivables par protéase et procédés d'utilisation associés |
WO2024040195A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
AU9127098A (en) | 1997-09-04 | 1999-03-22 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
EP1286700A2 (fr) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
EP1324771B2 (fr) | 2000-10-09 | 2018-06-06 | CytomX Therapeutics, Inc. | Anticorps thérapeutiques indusant la tolérance |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
CA2483912A1 (fr) | 2002-05-03 | 2003-11-13 | Raven Biotechnologies, Inc. | Alcam et modulateurs d'alcam |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
MXPA06007190A (es) | 2003-12-22 | 2006-08-23 | Glaxo Group Ltd | Inmunoglobulinas neutralizantes nogo-a para tratamiento de enfermedades neurologicas. |
US20090306347A1 (en) | 2005-08-29 | 2009-12-10 | Japan Science And Technology Agency | Antibody produced using ostrich and method for production thereof |
AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
JP5612247B2 (ja) | 2005-11-29 | 2014-10-22 | 独立行政法人科学技術振興機構 | Cd166に対するモノクローナル抗体およびその産生方法 |
CA2645347A1 (fr) | 2006-03-10 | 2007-09-20 | Diatos | Medicaments anticancereux conjugues a un anticorps au moyen d'un lieur dissociable par une enzyme |
JP5382692B2 (ja) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
JP2009055899A (ja) | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Adcc活性を増強させた抗体及びその製造方法 |
EP3492488A1 (fr) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci |
EP2192922A4 (fr) * | 2007-09-17 | 2010-09-29 | Univ California | Anticorps monoclonaux humains internalisants ciblant des cellules du cancer de la prostate<i>in situ</i> |
JP2011515073A (ja) | 2008-02-20 | 2011-05-19 | ジーツー インフラメイション プロプライエタリー リミテッド | ヒト化抗C5aR抗体 |
EP2276506A4 (fr) | 2008-04-30 | 2014-05-07 | Immunogen Inc | Conjugués puissants et coupleurs hydrophiles |
JP5756292B2 (ja) | 2008-12-22 | 2015-07-29 | 中外製薬株式会社 | 抗hs6st2抗体及びその用途 |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
ES2641612T3 (es) | 2009-04-17 | 2017-11-10 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos |
US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
EP2635301A4 (fr) | 2010-11-03 | 2016-06-01 | Immunogen Inc | Agents cytotoxiques comprenant de nouveaux dérivés d'ansamitocine |
JP2014519496A (ja) * | 2011-05-11 | 2014-08-14 | ナノヴァレント ファーマシューティカルズ,インコーポレイテッド | Alcam細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制 |
CN104540518A (zh) * | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
RU2015129551A (ru) | 2012-12-19 | 2017-01-25 | Эмплиммьюн, Инк. | Антитела к в7-н4 человека и их применение |
JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス,インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
US10765742B2 (en) | 2015-07-17 | 2020-09-08 | The Trustees Of Columbia University In The City Of New York | Methods of treating CD166-expressing cancer |
EP3371301A4 (fr) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | Procédés et compositions pour induire la différenciation de cellules hématopoïétiques |
WO2017218750A1 (fr) | 2016-06-15 | 2017-12-21 | The Cleveland Clinic Foundation | Nouveaux anticorps anti-cd6 pour le traitement d'affections induites par les lymphocytes t |
JP6183523B2 (ja) | 2016-09-14 | 2017-08-23 | 株式会社アンセイ | 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構 |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11376332B2 (en) | 2016-10-15 | 2022-07-05 | Baylor College Of Medicine | Platform for enhanced targeted delivery |
JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗pdl1抗体、およびその使用方法 |
JP2020531045A (ja) | 2017-07-14 | 2020-11-05 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd166抗体およびその使用 |
CN111212853A (zh) | 2017-08-30 | 2020-05-29 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
KR20210098989A (ko) | 2018-11-02 | 2021-08-11 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항-cd166 항체 및 이의 사용 방법 |
CN113677372A (zh) | 2019-02-26 | 2021-11-19 | 西托姆克斯治疗公司 | 可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法 |
-
2016
- 2016-05-04 IL IL292798A patent/IL292798A/en unknown
- 2016-05-04 WO PCT/US2016/030785 patent/WO2016179285A1/fr active Application Filing
- 2016-05-04 BR BR112017023872A patent/BR112017023872A2/pt not_active IP Right Cessation
- 2016-05-04 MX MX2017014136A patent/MX2017014136A/es unknown
- 2016-05-04 KR KR1020177034835A patent/KR20180010203A/ko active Search and Examination
- 2016-05-04 EP EP20155149.6A patent/EP3708585A1/fr active Pending
- 2016-05-04 PL PL16722502T patent/PL3292150T3/pl unknown
- 2016-05-04 PT PT167225028T patent/PT3292150T/pt unknown
- 2016-05-04 EP EP16722502.8A patent/EP3292150B1/fr active Active
- 2016-05-04 CA CA2984948A patent/CA2984948A1/fr active Pending
- 2016-05-04 AU AU2016257929A patent/AU2016257929B2/en not_active Expired - Fee Related
- 2016-05-04 EA EA201792414A patent/EA201792414A1/ru unknown
- 2016-05-04 RS RS20200511A patent/RS60222B1/sr unknown
- 2016-05-04 ES ES16722502T patent/ES2796698T3/es active Active
- 2016-05-04 US US15/146,603 patent/US10745481B2/en active Active
- 2016-05-04 HU HUE16722502A patent/HUE049866T2/hu unknown
- 2016-05-04 CN CN201680038634.3A patent/CN107849133B/zh not_active Expired - Fee Related
- 2016-05-04 DK DK16722502.8T patent/DK3292150T3/da active
- 2016-05-04 SG SG10202110908WA patent/SG10202110908WA/en unknown
- 2016-05-04 CN CN202210950237.0A patent/CN115340607A/zh active Pending
- 2016-05-04 SG SG10201913767VA patent/SG10201913767VA/en unknown
- 2016-05-04 JP JP2017557287A patent/JP7028648B2/ja active Active
-
2017
- 2017-11-02 IL IL255414A patent/IL255414B/en unknown
- 2017-11-03 MX MX2021014735A patent/MX2021014735A/es unknown
-
2018
- 2018-07-20 HK HK18109420.1A patent/HK1250036A1/zh unknown
-
2019
- 2019-12-20 US US16/723,809 patent/US11753466B2/en active Active
-
2020
- 2020-05-05 HR HRP20200721TT patent/HRP20200721T1/hr unknown
-
2022
- 2022-02-17 JP JP2022022910A patent/JP2022065115A/ja not_active Withdrawn
-
2023
- 2023-07-18 US US18/354,353 patent/US20240076374A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250036A1 (zh) | 抗cd 166抗體,可活化抗cd 166抗體及其使用方法 | |
HK1250037A1 (zh) | 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法 | |
IL254458A0 (en) | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them | |
IL270921A (en) | Activatable anti-PDL1 antibodies and methods of using them | |
HK1250035A1 (zh) | 抗cd 71抗體,可活化抗cd 71抗體及其使用方法 | |
HK1250033A1 (zh) | 抗-pd-1抗體、可活化的抗-pd-1抗體、及其使用方法 | |
HK1249445A1 (zh) | 抗分揀蛋白抗體和其使用方法 | |
IL259495A (en) | Antibodies and methods for using them | |
HK1252698A1 (zh) | 抗siglec-9抗體及其使用方法 | |
HK1252696A1 (zh) | 抗siglec-7抗體及其使用方法 | |
SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL270793A (en) | Anti-HTRA1 antibodies and methods of using them |